Literature DB >> 30096274

Bone-Modifying Agents: Complicated to Use.

Siyang Leng1, Suzanne Lentzsch1.   

Abstract

Mesh：

Year:  2018        PMID： 30096274     DOI： 10.1200/JOP.18.00444

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  3 in total

1.  How I treat a refractory myeloma patient who is not eligible for a clinical trial.

Authors:  Siyang Leng; Divaya Bhutani; Suzanne Lentzsch
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases.

Authors:  Joaquim Soares do Brito; Raquel Lopes-Brás; André Abrunhosa-Branquinho; Isabel Fernandes; Inês Gomes; Sandra Casimiro; Luís Costa
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639

3.  One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Vittorio Fusco; Giuseppina Campisi; Alberto Bedogni
Journal:  Support Care Cancer       Date:  2022-03-21       Impact factor: 3.359
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.